US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
Top-line data from a late-stage trial of Amgen’s Prolia in osteoporosis patients receiving glucocorticoid therapy show that all primary and secondary targets being investigated were met.